Committed to Transforming Lives Through Cellular Innovation
ReGrowth Biotech’s Mission & Vision
Our commitment to transforming hair restoration through cellular innovation is guided by clear principles that shape every aspect of our work. These foundational beliefs drive our scientific advancement, partnership development, and dedication to making revolutionary treatments accessible worldwide.
Our Mission
Deliver safe, effective, and personalised cellular solutions through continuous technological innovation and scientific excellence. We transform how healthcare providers approach hair restoration by providing breakthrough regenerative therapies that address root causes rather than symptoms, ensuring optimal patient outcomes worldwide
Our Vision
Unlocking life's possibilities through revolutionary cellular technology—for every body, every future. We envision a world where advanced cellular therapies make effective hair restoration accessible to patients globally through our network of healthcare partners, creating lasting transformation and renewed confidence.
Our Senior Leadership Team
Benno Jiao, MBA
CEO & Founder
Benno Jiao founded RE-Stem in 2012 and brings over 20 years of experience in the biotech and medical industries. As a serial entrepreneur, he has founded or co-founded over three healthcare and biotechnology companies, including Cellular Biomedicine Group (a biotech company listed on NASDAQ) and Tarcine Medicine. Jiao holds over eight patents under his name and serves as a member of China's National Standardization Technical Committee and as a Member of the Board of Renmin University of China.
He graduated from the University of Pittsburgh in 1999 with a double bachelor's degree in science and business psychology, and earned his MBA from Marshall Business School at the University of Southern California in 2003. Under his leadership, ReGrowth Biotech has pioneered the D.P.G. technology platform and established global operations spanning multiple continents.
Dr Jyothi Devakumar guides scientific strategy as Chief Science Officer at ReGrowth Biotechnology, where cellular medicine offers new possibilities for hair regeneration. Having completed a PhD in Biotechnology in 2001, Dr Devakumar applies deep knowledge of regenerative medicine and cell therapy to address meaningful challenges in dermatological health. At ReGrowth, Dr Devakumar oversees development of the D.P.G. technology that enables patients' own dermal papilla cells to stimulate new hair follicle growth.
Dr Devakumar's career encompasses leadership roles in regenerative medicine organisations, teaching as a medical university professor, and investment analysis, including an Oxford diploma in finance. Previous appointments include Director of Scientific Projects at Healthspan Action Coalition and CSO positions at Longevitytech.fund and HealthyLongevity.clinic. This varied experience informs a measured, evidence-based approach to advancing cellular technologies that can transform hair restoration outcomes.
Jyothi Devakumar, PhD
Chief Scientific Officer
Judyanna Yu brings over 10 years of executive experience in publicly traded companies and conglomerates. Her background includes serving as CFO of Biochem Group, a publicly listed healthcare company, where she also oversaw operations in Canada. She previously held the position of VP of Finance and Corporate Development for IFDS, a joint venture of State Street Bank and DST with consolidated revenue exceeding $500 million.
Ms Yu was instrumental as a strategic partner in building the China Specialty Practice for her accounting firm, helping it reach the top two position in Canada, immediately following EY. She articled at KPMG after graduating with a Bachelor of Commerce degree with distinction from the University of Alberta and holds certifications as CPA, CA, and CPA (Washington).
Judyanna Yu
Chief Financial Officer
Steven Schweller
President of International Business Development
Steve Schweller leads investment and partnership opportunities globally. He brings extensive entrepreneurship experience across three continents: the Americas, Europe, and Asia, specialising in high-growth and breakthrough industries such as European real estate and China healthcare and biotechnology. Steve has worked at the grassroots and fundraising levels of several Chinese healthcare and biotech firms that have successfully listed on the NASDAQ exchange.
With a proven track record of matching exceptional investment opportunities with sophisticated investors whilst mitigating risks, Steve has successfully navigated through both calm and turbulent markets. His extensive experience in breakthrough industries and deep understanding of Asian markets makes him instrumental in ReGrowth Biotech's international expansion and partnership development strategy.
Built on 10-Years of Scientific Excellence
Our development timeline includes key milestones: beginning in 2012 with research into autologous adipose-derived mesenchymal stem cells, progressing through dedicated hair follicle stem cell research from 2016, and culminating in our breakthrough D.P.G. technology validation.
2023
First regenerative outcomes observed in clinical applications, including the landmark chemical burn patient case that demonstrated our technology's remarkable capabilities
2024
Validation of our D.P.G. technology through over 400 successful applications and comprehensive animal testing, establishing the scientific foundation for global expansion
2025
Continued expansion and stablishment of our network of collaborative clinical institutions across the globe and 16 D.P.G. technology laboratories operating internationally
Corporate Structure
ReGrowth Biotech operates as an independent subsidiary of Restem Biotech, combining the focused expertise of a specialist cellular hair restoration company with the broader resources and capabilities of an established biotechnology organisation.
This structure enables us to maintain dedicated focus on hair regeneration and aesthetic applications whilst leveraging shared research capabilities and global infrastructure for accelerated innovation and market development.